Sign In
Buy RHHBY
$49.06
-0.130 (-0.264%)
At Close: Jun 03, 2026
Roche to advance prasinezumab into Phase III development for early-stage Parkinson's disease
01:00am, Monday, 16'th Jun 2025
Basel, 16 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today its decision to proceed with Phase III development of prasinezumab, an investigational anti-alpha-synuclein antibody, in early-
Basel, 15 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new dosing restrictions, effective immediately, for ELEVIDYS™ (delandistrogene moxeparvovec), for non-ambulatory Duchenne mus
EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio
04:08am, Wednesday, 11'th Jun 2025
STOCKHOLM, June 11, 2025 /PRNewswire/ -- EQT Life Sciences is pleased to announce that the LSP 7 fund has invested in SpliceBio. The Spanish biotech company is developing novel therapies for genetic d
Access Medical Labs, a Subsidiary of Empresas Aries, Completes Historic Lab Expansion with Roche Diagnostics Systems
12:10pm, Tuesday, 10'th Jun 2025
JUPITER, Fla., June 10, 2025 (GLOBE NEWSWIRE) -- In a milestone rarely achieved in the clinical laboratory industry, Access Medical Labs — the largest private diagnostic lab in Florida — has compl
$101.5 Bn Oncology Diagnostics Global Markets, 2023-2024 & 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche.
06:19am, Tuesday, 10'th Jun 2025
The global oncology diagnostics market is projected to grow from $77.6 billion in 2024 to $101.5 billion by 2029. Key growth drivers include rising cancer rates, R&D, new product launches, and expansi
Green Steel Industry Report 2025-2029 with Profiles of Leading Players - F. Hoffmann-La Roche.
05:44am, Tuesday, 10'th Jun 2025
The Green Steel Market, valued at USD 7.4 billion in 2024, is expected to reach USD 19.4 billion by 2029, growing at a CAGR of 21.4%. The market is driven by innovative technologies such as electric a
Health Rounds: Roche's Tecentriq reduces recurrence, deaths for certain colon cancer patients
07:04am, Friday, 06'th Jun 2025
Adding Roche's immunotherapy drug Tecentriq to chemotherapy after surgery in certain patients whose colon cancer had spread to the lymph nodes led to a 50% reduction in cancer recurrence and death com
I own gold, yen and German bunds, 'won't own U.S. treasuries at all': David Roche
09:52pm, Wednesday, 04'th Jun 2025
David Roche from Quantum Strategy criticizes President Trump's intention to influence the Fed on monetary policy.
Roche's Evrysdi tablet approved by European Commission as first and only for Spinal Muscular Atrophy (SMA)
01:00am, Wednesday, 04'th Jun 2025
Basel, 04 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Commission (EC) has approved a label extension for Evrysdi® (risdiplam) to include a new, room-temperature s
Roche's Tecentriq With Lurbinectedin Increases Survival to Small-Cell Lung Cancer, Study Says
02:08am, Tuesday, 03'rd Jun 2025
The pharmaceutical company said late-stage trials showed that Tecentriq combined with lurbinectedin led to a 46% reduction in the risk of the disease progressing or death.
Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
01:00am, Tuesday, 03'rd Jun 2025
Basel, 3 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination with lurbinectedin (Zepzelca®) a
Genentech's Tecentriq Combined with Lurbinectedin Shows Significant Survival Benefit in Extensive-Stage Small Cell Lung Cancer
04:05pm, Monday, 02'nd Jun 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atez
New data show Roche's Itovebi significantly extended survival in a certain type of HR-positive advanced breast cancer
08:05am, Saturday, 31'st May 2025
Basel, 31 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive final results from the overall survival (OS) analysis of the phase III INAVO120 study. These data showed ItovebiTM (ina
New Data Show Genentech's Itovebi Significantly Extended Survival in a Certain Type of HR-positive Advanced Breast Cancer
08:05am, Saturday, 31'st May 2025
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, 96-week data for fenebrutinib demonstrating that patients with r
